Controlled evaluation of angiotensin receptor blockers for covid-19 respiratory disease (clarity): statistical analysis plan for a randomised controlled bayesian adaptive sample size trial

HIGHLIGHTS

SUMMARY

    The CLARITY trial is a two-arm, multi-centre, comparative effectiveness phase III randomised controlled Bayesian adaptive trial, conducted in India and Australia. The approach reduces the risk of an indeterminate outcome and ensures the trial does not continue recruiting participants beyond the point where conclusive evidence of benefit is found. The CLARITY trial statistical analysis plan (SAP) was developed following the Guidelines for the Content of Statistical Analysis Plans in Clinical Trials and includes pre-specified decision rules for continuing or stopping the trial based on effectiveness or futility. The first planned analysis . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?